内分泌治疗联合曲妥珠单抗和帕妥珠单抗对比降阶梯化疗在激素受体阳性/ERBB2阳性早期乳腺癌患者中的疗效:新辅助WSG-TP-II随机临床试验
这项前瞻性多中心新辅助随机临床试验纳入207例激素受体阳性/ERBB2阳性早期乳腺癌患者,比较12周标准内分泌治疗联合曲妥珠单抗和帕妥珠单抗与紫杉醇联合曲妥珠单抗和帕妥珠单抗的疗效。内分泌治疗组pCR率为23.7%,紫杉醇组为56.4%(OR 0.24,95%CI 0.12-0.46,P<.001)。紫杉醇方案在ERBB2 mRNA最高四分位组未显示优于内分泌治疗,而内分泌治疗组12周后未观察到健康相关生活质量下降。
要点
- 紫杉醇联合双靶向组pCR率56.4%,显著高于内分泌治疗联合双靶向组的23.7%(OR 0.24,P<.001)。
- ERBB2免疫组化评分≥3和ERBB2富集亚型是两组pCR的独立预测因素。
- 紫杉醇仅在ERBB2 mRNA第一至第三四分位组优于内分泌治疗,最高四分位组未显示优势。
核心结论
- WSG-TP-II试验首次前瞻性比较了两种新辅助降阶梯治疗在激素受体阳性/ERBB2阳性早期乳腺癌中的疗效,12周紫杉醇联合曲妥珠单抗和帕妥珠单抗的pCR率明显优于内分泌治疗联合曲妥珠单抗和帕妥珠单抗。
研究设计与样本
- 前瞻性、多中心、新辅助随机临床试验,纳入207例经中心确认的雌激素受体阳性和/或孕激素受体阳性(>1%)激素受体阳性/ERBB2阳性早期乳腺癌患者。
- 患者随机分配至12周标准内分泌治疗(芳香化酶抑制剂或他莫昔芬)联合曲妥珠单抗和帕妥珠单抗组(n=100)或紫杉醇联合曲妥珠单抗和帕妥珠单抗组(n=107)。
- 研究需186例患者以检测pCR的统计学显著差异(假设pCR绝对差异19%,把握度≥80%,单侧Fisher精确检验,显著性水平2.5%)。
- 紫杉醇剂量为80 mg/m2每周一次,曲妥珠单抗和帕妥珠单抗每21天一次;pCR患者允许省略进一步化疗。
- 对基线肿瘤活检进行PAM50分析。
主要发现
- 207例患者中位年龄53岁(范围25-83岁),121例(58%)为cT2至cT4肿瘤,58例(28%)为临床淋巴结阳性早期乳腺癌。
- 内分泌治疗联合曲妥珠单抗和帕妥珠单抗组pCR率为23.7%(95%CI 15.7%-33.4%),紫杉醇联合曲妥珠单抗和帕妥珠单抗组为56.4%(95%CI 46.2%-66.3%),比值比0.24(95%CI 0.12-0.46),P<.001。
- ERBB2免疫组化评分≥3和ERBB2富集亚型在两组中均为pCR的独立预测因素。
- 紫杉醇仅在ERBB2 mRNA第一至第三四分位组优于内分泌治疗,在最高ERBB2四分位组未显示优势。
- 与紫杉醇联合曲妥珠单抗和帕妥珠单抗组不同,内分泌治疗联合曲妥珠单抗和帕妥珠单抗组12周后未观察到健康相关生活质量下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Combination of chemotherapy with (dual) ERBB2 blockade is considered standard in hormone receptor (HR)-positive/ERBB2-positive early breast cancer (EBC). Despite some promising data on endocrine therapy (ET) combination with dual ERBB2 blockade in HR-positive/ERBB2-positive BC, to our knowledge, no prospective comparison of neoadjuvant chemotherapy vs ET plus ERBB2 blockade in particular with focus on molecular markers has yet been performed. OBJECTIVE: To determine whether neoadjuvant de-escalated chemotherapy is superior to endocrine therapy, both in combination with pertuzumab and trastuzumab, in a highly heterogeneous HR-positive/ERBB2-positive EBC. DESIGN, SETTING, AND PARTICIPANTS: This prospective, multicenter, neoadjuvant randomized clinical trial allocated 207 patients with centrally confirmed estrogen receptor-positive and/or progesterone receptor-positive (>1%) HR-positive/ERBB2-positive EBC to 12 weeks of standard ET (n = 100) vs paclitaxel (n = 107) plus trastuzumab and pertuzumab. A total of 186 patients were required to detect a statistically significant difference in pathological complete response (pCR) (assumptions: 19% absolute difference in pCR; power, ≥80%; 1-sided Fisher exact test, 2.5% significance level). INTERVENTIONS: Standard ET (aromatase inhibitor or tamoxifen) or paclitaxel, 80 mg/m2, weekly plus trastuzumab and pertuzumab every 21 days. MAIN OUTCOMES AND MEASURES: The primary end point was pCR (ypT0/is, ypN0). Secondary end points included safety, translational research, and health-related quality of life. Omission of further chemotherapy was allowed in patients with pCR. PAM50 analysis was performed on baseline tumor biopsies. RESULTS: Of the 207 patients included (median [range] age, 53 [25-83] years), 121 (58%) had cT2 to cT4 tumors, and 58 (28%) had clinically node-positive EBC. The pCR rate in the ET plus trastuzumab and pertuzumab arm was 23.7% (95% CI, 15.7%-33.4%) vs 56.4% (95% CI, 46.2%-66.3%) in the paclitaxel plus trastuzumab and pertuzumab arm (odds ratio, 0.24; 95% CI, 0.12-0.46; P < .001). Both immunohistochemical ERBB2 score of 3 or higher and ERBB2-enriched subtype were independent predictors for pCR in both arms. Paclitaxel was superior to ET only in the first through third quartiles but not in the highest ERBB2 quartile by messenger RNA. In contrast with the paclitaxel plus trastuzumab and pertuzumab arm, no decrease in health-related quality of life after 12 weeks was observed in the ET plus trastuzumab and pertuzumab arm. CONCLUSIONS AND RELEVANCE: The WSG-TP-II randomized clinical trial is, to our knowledge, the first prospective trial comparing 2 neoadjuvant de-escalation treatments in HR-positive/ERBB2-positive EBC and demonstrated an excellent pCR rate after 12 weeks of paclitaxel plus trastuzumab and pertuzumab that was clearly superior to the pCR rate after ET plus trastuzumab and pertuzumab. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03272477.
引用
- Gluz O, Nitz UA, Christgen M, et al. Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 37166817. doi:10.1001/jamaoncol.2023.0646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。